Acura Pharmaceuticals Meets NASDAQ’s Continuing Listing Requirement
Palatine, IL - (September 16, 2015) -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) (the “Company”), announced that on September 15, 2015, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market confirming that for the last 10 consecutive business days, from August 28 to September 14, 2015, the closing bid price of the Company’s common stock has been equal to or in excess of the $1.00 per share minimum bid price requirement for continued listing, as required by Nasdaq Listing Rule 5550(a)(2) and the Company was once again in compliance with the rule. The letter further stated that this matter, which had been previously communicated to the Company in the Staff’s non-compliance notices dated September 18, 2014 and March 19, 2015, is now closed.
“We are pleased to have satisfied the listing requirement and that our common stock will continue to trade on The NASDAQ Capital Market”, commented Peter Clemens, Sr. VP and CFO of Acura. “We believe this allows for broader interest by institutional investors and greater liquidity for all shareholders.”
